SPY332.11+2.05 0.62%
DIA272.00+3.59 1.34%
IXIC10,998.40+57.23 0.52%

Goldman Sachs Initiates Coverage On Teva Pharmaceutical Indus with Neutral Rating, Announces Price Target of $12

Goldman Sachs analyst Nathan Rich initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Neutral rating and announces Price Target of $12.

Benzinga · -
Goldman Sachs analyst Nathan Rich initiates coverage on Teva Pharmaceutical Indus (NYSE: TEVA) with a Neutral rating and announces Price Target of $12.